Curcumin-Loaded In-Situ Gel for Ocular Complications in Diabetes Mellitus: A Novel Approach in Targeted Ocular Therapy

Abstract

Ocular complications are a common and severe consequence of uncontrolled diabetes mellitus, particularly diabetic retinopathy (DR), diabetic macular edema (DME), and cataracts. These disorders arise primarily from prolonged hyperglycemia, oxidative stress, and inflammation. Curcumin, a bioactive compound derived from the rhizome of Curcuma longa, exhibits potent antioxidant, anti-inflammatory, and anti-angiogenic properties, making it a suitable candidate for managing diabetic ocular complications. However, its clinical application is limited by poor aqueous solubility and low bioavailability. Recent advances in drug delivery systems, especially in-situ gel formulations, offer a promising strategy to overcome these limitations. This review explores the pathophysiology of diabetic ocular complications, the therapeutic potential of curcumin, and how in-situ gel technology enhances curcumin's ocular bioavailability and therapeutic efficacy.

Keywords

Diabetes mellitus, Curcumin, Targeted Ocular Therapy.

Introduction

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia due to defects in insulin secretion, insulin action, or both.

According to the World Health Organization (WHO), the global burden of diabetes continues to rise, with a significant portion of patients developing complications over time. Among the many complications of diabetes, ocular complications are among the most prevalent and visually debilitating.

The global rise in diabetes mellitus poses a significant public health challenge, with its complications affecting nearly every organ system, including the eyes. Vision-related problems are among the most feared consequences of diabetes, as they can severely impair a patient's independence and quality of life.

The World Health Organization estimates that diabetic retinopathy alone accounts for about 4.8% of global cases of blindness. As diabetes becomes more prevalent in younger populations, the burden of ocular diseases associated with it is expected to grow exponentially.

Ocular complications are a common and severe consequence of uncontrolled diabetes mellitus, particularly diabetic retinopathy (DR), diabetic macular edema (DME), and cataracts. These disorders arise primarily from prolonged hyperglycemia, oxidative stress, and inflammation. While standard treatments such as anti-VEGF injections, corticosteroids, and laser photocoagulation are available, these approaches are often invasive, expensive, and may come with side effects or poor patient compliance.

In recent years, the field of ocular pharmacotherapy has seen a surge in interest toward developing targeted, sustained-release drug delivery systems to overcome the limitations of traditional eye drops and invasive treatments. The eye is a complex and protected organ, and achieving therapeutic drug levels within its inner structures remains a formidable task.

Topical eye drops often fail due to rapid tear drainage, blinking, and low permeability across corneal barriers. In contrast, in-situ gelling systems have emerged as innovative platforms that can transform from a solution to a gel upon application, thus providing prolonged contact time, enhanced bioavailability, and reduced dosing frequency.

Among the many therapeutic agents under investigation, curcumin, a bioactive polyphenolic compound derived from the rhizome of Curcuma longa, has garnered substantial attention due to its broad spectrum of pharmacological activities.

Its potent antioxidant, anti-inflammatory, and anti-angiogenic properties make it a promising candidate for managing diabetic ocular complications. However, its clinical application is hindered by poor aqueous solubility, low bioavailability, and rapid metabolism.

This review focuses on the integration of curcumin into in-situ gelling systems for ocular application, particularly targeting complications arising from diabetes mellitus. It explores the pathophysiological basis of diabetic eye diseases, the mechanistic roles of curcumin, and the design strategies behind in-situ gels that can optimize its therapeutic potential.

This novel combination not only represents a scientific advancement in drug delivery but also offers hope for improving ocular health and visual outcomes in millions of diabetic patients worldwide.

Common ocular complications of diabetes include:

Diabetic retinopathy (DR) – Damage to the retinal microvasculature leading to vision loss.

Diabetic macular edema (DME) – Swelling of the central retina due to fluid accumulation.

Cataracts – Clouding of the lens due to glycation and oxidative stress.

Glaucoma – Increased intraocular pressure causing optic nerve damage.

The pathogenesis of these disorders is multifactorial, involving oxidative stress, inflammation, and vascular endothelial growth factor (VEGF)-mediated neovascularization. While standard treatments like anti-VEGF injections and laser therapy exist, they come with limitations like invasiveness, high cost, and patient discomfort.

2. CURCUMIN: A Promising Natural Therapeutic Agent

Curcumin is a polyphenolic compound responsible for the yellow color of turmeric. Structurally, it is a diarylheptanoid with the formula C??H??O?. Its wide range of pharmacological effects has been validated in numerous preclinical and clinical studies.

Pharmacological Properties Relevant to Ocular Complications:

Antioxidant Activity: Curcumin neutralizes free radicals and upregulates endogenous antioxidant enzymes like superoxide dismutase (SOD), catalase, and glutathione peroxidase.

Anti-inflammatory Effect: Curcumin inhibits pro-inflammatory transcription factors such as NF-κB, thereby reducing the expression of cytokines like TNF-α, IL-1β, and IL-6.

Anti-angiogenic Action: It downregulates VEGF, reducing abnormal blood vessel formation in the retina.

Neuroprotective and Anti-apoptotic Properties: Curcumin protects retinal ganglion cells from apoptosis induced by hyperglycemia and oxidative stress.

Despite these benefits, curcumin's clinical use is limited due to its:

• Poor aqueous solubility (∼11 ng/mL),
• Rapid metabolism and systemic elimination,
• Low ocular penetration when administered topically or orally.

Hence, novel formulations are needed to maximize its therapeutic effects in ocular diseases.

3. OCULAR DRUG DELIVERY:

Challenges and Opportunities

Delivering drugs to the eye is inherently difficult due to:

1. Anatomical barriers (corneal epithelium, blood-retinal barrier),
2. Physiological barriers (tear turnover, blinking, drainage),
3. Limited residence time of formulations in the eye.

Conventional eye drops typically have a retention time of only 2-5 minutes and result in poor drug absorption (<5% of administered dose reaches intraocular tissues).

In-situ Gels: An Advanced Drug Delivery System

In-situ gels are polymer-based formulations that undergo liquid-to-gel transformation upon exposure to physiological conditions such as:

Temperature (Thermosensitive gels) – e.g., Pluronic F127 gels at body temperature.

pH (pH-sensitive gels) – e.g., Carbopol gels that gel at ocular pH.

Ionic strength (Ion-sensitive gels) – e.g., Gellan gum which gels in the presence of tear ions.

Advantages:

• Prolonged ocular residence time,
• Reduced dosing frequency,
• Enhanced corneal contact and penetration,
• Minimal discomfort and better patient compliance.

4. CURCUMIN-LOADED IN-SITU GEL FORMULATION

Formulating curcumin into an in-situ gel requires overcoming its hydrophobicity. Strategies include:

1. Nanoparticle Encapsulation:

Curcumin can be encapsulated in biodegradable nanoparticles (e.g., PLGA, chitosan) to improve solubility, protect it from degradation, and ensure controlled release.

2. Use of Solubilizers:

Cyclodextrins, surfactants, or co-solvents like ethanol can increase curcumin solubility before incorporating it into the gel matrix.

3. Polymer System:

Pluronic F127 + HPMC: For thermosensitive gelation.

Carbopol 940 + Sodium alginate: For pH and ion-sensitive behavior.

These polymers are mucoadhesive and form a transparent gel suitable for ocular use.

4. Formulation Optimization:

Parameters like viscosity, pH, gelling temperature, drug release kinetics, and sterility are carefully optimized to ensure ocular safety and effectiveness.

5. MECHANISM OF THERAPEUTIC ACTION

After administration into the eye, the formulation undergoes gelation upon contact with the tear fluid. The gel forms a thin layer over the ocular surface, allowing sustained release of curcumin.

Curcumin, the principal curcuminoid derived from the rhizome of Curcuma longa (turmeric), exhibits a diverse and potent pharmacological profile that makes it a promising candidate for treating various ocular complications, particularly those arising from diabetes mellitus.

Its efficacy is largely attributed to its ability to modulate multiple cellular signaling pathways and counteract oxidative stress, inflammation, and abnormal angiogenesis—all of which are key pathological features in diabetic retinopathy and other related disorders.

Antioxidant Activity:

Curcumin is a powerful free radical scavenger. In diabetic conditions, elevated blood glucose levels lead to increased production of reactive oxygen species (ROS), which damage retinal cells, disrupt the blood-retinal barrier, and promote disease progression. Curcumin mitigates this damage by enhancing the activity of endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), thereby protecting retinal tissues from oxidative injury.

Anti-inflammatory Properties:

Chronic inflammation is a hallmark of diabetic eye diseases. Curcumin downregulates inflammatory cytokines like TNF-α, IL-1β, and IL-6 by inhibiting the activation of nuclear factor-kappa B (NF-κB), a key transcription factor involved in inflammatory signaling. By modulating these pro-inflammatory mediators, curcumin helps preserve retinal structure and function.

Anti-angiogenic and Anti-proliferative Effects:

One of the major complications in diabetic retinopathy is pathological neovascularization driven by vascular endothelial growth factor (VEGF). Curcumin inhibits the expression of VEGF and other angiogenic factors, thereby suppressing abnormal blood vessel formation. This action is crucial in preventing vision-threatening complications such as macular edema and vitreous hemorrhage.

Neuroprotective Potential:

Emerging studies have demonstrated curcumin’s role in neuroprotection by promoting neuronal survival, reducing apoptosis, and maintaining the integrity of retinal ganglion cells. This is particularly significant since neurodegeneration in the retina often precedes visible vascular damage in diabetic retinopathy.

Antibacterial and Wound Healing Properties:

Curcumin also exhibits mild antibacterial properties, which may be beneficial in preventing secondary infections in the eye. Moreover, it supports tissue repair and regeneration, which is advantageous in the healing of damaged ocular tissues.

Challenges in Ocular Use:

Despite these benefits, curcumin suffers from poor aqueous solubility, low stability in physiological pH, and rapid systemic metabolism, which severely limit its therapeutic efficacy when administered orally or topically in conventional formulations. Therefore, incorporating curcumin into advanced delivery systems—such as in-situ gels—can help overcome these limitations by enhancing solubility, sustaining release, and increasing bioavailability directly at the site of action.

6. PRECLINICAL EVIDENCE

Several animal studies have demonstrated the potential of curcumin-loaded ocular delivery systems:

In streptozotocin-induced diabetic rats, curcumin-loaded nanogels reduced retinal damage, decreased VEGF expression, and improved retinal thickness.

Histopathological examination showed reduced inflammatory cell infiltration and preserved retinal architecture.

Pharmacokinetic studies indicated that in-situ gels maintained therapeutic drug levels for up to 12–24 hours.

7. CLINICAL PERSPECTIVES AND SAFETY

Although human clinical trials are limited, curcumin has been shown to be safe for ocular use in topical formulations. It is non-toxic to corneal and conjunctival tissues at therapeutic concentrations. Additionally, in-situ gels avoid systemic exposure, further reducing the risk of side effects.

Future clinical studies should focus on:

Evaluating long-term safety and efficacy in diabetic patients,

Comparing curcumin-loaded gels with existing treatments (e.g., anti-VEGF injections),

Studying effects on visual acuity, macular thickness, and DR progression.

8. ADVANTAGES OVER CONVENTIONAL THERAPIES

1. Enhanced Bioavailability: Improved solubility and sustained release result in higher curcumin levels in ocular tissues.
2. Minimized Side Effects: Localized delivery reduces systemic exposure and potential toxicity.
3. Non-Invasive: Unlike intravitreal injections, in-situ gels are administered topically.
4. Patient Compliance: Easy instillation and less frequent dosing improve adherence to therapy.
5. Multifunctional Effect: Curcumin acts on multiple pathological pathways simultaneously.

9. LIMITATIONS AND CHALLENGES

Despite the promising pharmacological profile and potential of curcumin-loaded in-situ gel systems, several limitations and challenges must be addressed to ensure successful clinical translation and large-scale applicability.

1. Poor Aqueous Solubility and Stability

Curcumin is highly lipophilic, with very low solubility in aqueous media, which limits its availability in tear fluid and ocular tissues.

It also undergoes rapid hydrolysis and photodegradation, making formulation and storage challenging.

These issues may compromise drug release, bioavailability, and therapeutic effect if not properly addressed through advanced carriers or stabilizers.

2. Limited Ocular Penetration

The corneal epithelium is a major barrier to drug penetration, especially for large, lipophilic molecules like curcumin.

Even with in-situ gel systems, achieving sufficient drug concentrations in the posterior segment (e.g., retina) remains difficult without enhancers or nanoformulations.

3. Lack of Human Clinical Data

Most current evidence is derived from in vitro or animal studies. Human clinical trials are still lacking.

Without robust clinical efficacy and safety data, regulatory approval and physician adoption may face delays.

4. Formulation Complexity

Developing optimized, reproducible in-situ gels requires careful selection of gelling agents, stabilizers, and excipients.

Achieving the right balance between viscosity, gelation trigger (pH/temperature/ions), and drug release profile is technically demanding and needs substantial R&D.

5. Scalability and Manufacturing Concerns

Scaling up curcumin-based ocular formulations can be difficult due to:

Batch-to-batch variation in natural curcumin.

The need for sterile, preservative-free environments to ensure ocular safety.

This may increase production costs and limit affordability for widespread patient use.

6. Regulatory and Standardization Barriers

Herbal compounds like curcumin fall into a gray area between pharmaceuticals and nutraceuticals, making regulatory approval more complex.

Standardization of curcumin purity and content is essential to ensure consistency, which remains a challenge with natural sources.

7. Patient Variability and Compliance

Individual differences in tear composition, blinking rate, and ocular surface pH can influence gel formation and drug absorption.

While in-situ gels reduce dosing frequency, patient compliance still depends on clear instructions and proper administration technique.

8. Possible Ocular Irritation or Hypersensitivity

Some polymers or curcumin degradation products may cause mild irritation or allergic reactions, especially in sensitive individuals.

Long-term safety of repeated use in delicate ocular tissues is yet to be thoroughly established.

9. Environmental and Storage Sensitivity

Curcumin is light-sensitive and pH-labile, requiring special packaging and storage conditions (e.g., dark containers, cool environments).

These requirements can complicate distribution and handling in real-world settings.

10. FUTURE DIRECTIONS

Future Directions for review on Curcumin-loaded in-situ gel for ocular complications due to diabetes mellitus:

While curcumin-loaded in-situ gel systems have shown promising results in preclinical studies, several avenues remain to be explored to facilitate their transition from laboratory research to routine clinical use. Future research can be directed toward the following key areas:

1. Clinical Trials and Human Studies

Most current data come from in vitro studies or animal models. There is an urgent need for:

Phase I and II clinical trials to assess safety, tolerability, and ocular bioavailability in humans.

Evaluation of therapeutic efficacy in various stages of diabetic retinopathy and other ocular complications.

Patient-centered studies to understand compliance, dosing convenience, and long-term outcomes.

2. Advanced Formulation Technologies

Further innovation in formulation techniques can improve the stability, penetration, and therapeutic efficacy of curcumin:

Nanoparticle or micelle incorporation within the in-situ gel to enhance corneal permeability and solubility.

Hybrid systems like nanoemulsion-based in-situ gels for better drug dispersion and prolonged retention.

Use of stimuli-responsive polymers (temperature, pH, or ion-sensitive gels) to enhance gelation precision and retention time.

3. Combination Therapies

Curcumin could be used in combination with:

Other phytoconstituents like resveratrol or quercetin for synergistic effects.

Anti-VEGF agents or corticosteroids to create a multifaceted approach against diabetic retinopathy.

Formulation with vitamin E, lutein, or omega-3 fatty acids to provide neuroprotective and vascular benefits.

4. Drug Delivery Enhancements

Future studies could focus on:

Mucoadhesive polymers to further increase the residence time on the ocular surface.

Penetration enhancers or enzyme inhibitors to improve the transport of curcumin across the corneal barrier.

Contact lens-based in-situ systems or ocular inserts loaded with curcumin for prolonged release.

5. Personalized Medicine and Targeted Delivery

With the rise of pharmacogenomics, future strategies could explore:

Tailoring formulations based on patient-specific pathology or genetic predisposition to diabetic complications.

Targeted drug delivery using ligand-conjugated gels that bind specifically to damaged retinal tissues or over expressed receptors (e.g., RAGE or VEGF receptors).

6. Regulatory and Commercial Aspects

Addressing the regulatory requirements for herbal-based novel drug delivery systems.

Standardization of curcumin extracts, ensuring batch-to-batch consistency and quality.

Development of cost-effective production techniques to make the therapy accessible for broader patient populations.

7. Long-Term Safety and Stability Studies

Comprehensive toxicological evaluations to ensure no adverse effects on ocular tissues upon repeated administration.

Shelf-life and storage condition studies to determine the long-term stability of curcumin in the in-situ gel matrix.

CONCLUSION

Curcumin-loaded in-situ gel formulations represent a paradigm shift in the treatment of diabetic ocular complications. By leveraging curcumin’s multifaceted therapeutic actions—antioxidant, anti-inflammatory, anti-angiogenic, and neuroprotective—and the benefits of in-situ gelling systems, this approach offers a non-invasive, sustained, and targeted therapy for managing eye disorders associated with diabetes mellitus.

The in-situ gel system enhances ocular retention, improves bioavailability, and ensures a controlled and localized release of curcumin, thereby minimizing systemic side effects and maximizing therapeutic outcomes. As compared to conventional eye drops and invasive intravitreal injections, this formulation provides better patient compliance, reduced dosing frequency, and potential cost-effectiveness.

While preclinical evidence strongly supports the efficacy of curcumin-loaded in-situ gels in ameliorating diabetic eye complications, further research, including human clinical trials, is essential to validate their long-term safety, stability, and therapeutic superiority. Moreover, advancements in formulation science, such as the integration of nanocarriers and smart gel technologies, can further enhance the potential of this approach.

In conclusion, the curcumin-loaded in-situ gel system offers a promising and innovative solution to a long-standing clinical challenge. With continued interdisciplinary research and pharmaceutical development, this novel strategy could emerge as a reliable and effective therapy for preserving vision and improving the quality of life in patients suffering from diabetic ocular diseases.

REFERENCES

1. Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. International Journal of Biochemistry & Cell Biology, 41(1), 40–59.
2. Al-Kinani, A. A., Zidan, A. S., Elsaid, N., & Ahmad, M. Z. (2018). Ocular drug delivery systems: An overview. International Journal of Pharmaceutics, 543(1-2), 23–39.
3. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics, 4(6), 807–818.
4. Arafa, M. G., Ayoub, B. M., & El-Kersh, D. M. (2020). Eye drops of nano-curcumin-loaded PLGA nanoparticles in thermosensitive in situ gel for the treatment of diabetic retinopathy. AAPS PharmSciTech, 21(6), 1–11.
5. Bhatia, D., & Sharma, A. (2020). Role of curcumin in diabetic retinopathy: A review. Journal of Ocular Pharmacology and Therapeutics, 36(2), 76–85.
6. Calvo, P., Vila-Jato, J. L., & Alonso, M. J. (1997). Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. International Journal of Pharmaceutics, 153(1), 41–50.
7. Chaurasiya, P., Ganju, E., Upmanyu, N., Ray, S. K., & Jain, A. (2016). Ocular drug delivery systems: A review. World Journal of Pharmacy and Pharmaceutical Sciences, 5(6), 558–579.
8. Chen, Y., Lu, W. L., Gu, W., Huang, M., & Zhang, Q. (2010). Enhanced ocular bioavailability of ganciclovir by ion-activated in situ gel. Drug Delivery, 17(1), 63–68.
9. Gupta, H., Sharma, A., & Kumar, S. (2021). Ocular drug delivery systems: A review of challenges and advancements. Current Drug Delivery, 18(4), 468–485.
10. Jain, R., & Jain, N. (2015). In-situ gelling system for ocular drug delivery: a review. Journal of Drug Delivery and Therapeutics, 5(3), 1–5.
11. Kalaiselvan, R., Mohanta, G. P., & Manna, P. K. (2009). Design and evaluation of sodium alginate-based in situ gelling systems for ocular drug delivery. International Journal of Pharmacy and Pharmaceutical Sciences, 1(2), 109–117.
12. Kaur, I. P., & Kanwar, M. (2002). Ocular preparations: the formulation approach. Drug Development and Industrial Pharmacy, 28(5), 473–493.
13. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1–18.
14. Lall, R., & Adhami, V. M. (2021). Curcumin as a promising anticancer agent: Mechanisms of action and potential clinical applications. Biomedicine & Pharmacotherapy, 139, 111595.
15. Lin, T., Chen, L., Wang, R., et al. (2016). Curcumin reduces retinal inflammation in diabetic rats by blocking NF-κB signaling pathway. International Journal of Ophthalmology, 9(4), 485–490.
16. Mandal, S. C., & Mandal, M. (2019). Advanced ocular drug delivery systems: Challenges and innovations. Drug Delivery and Translational Research, 9(2), 337–346.
17. Maiti, S., Kaity, S., Ray, S., & Sa, B. (2011). Development and evaluation of xanthan gum-based sustained release matrix tablets of isosorbide-5-mononitrate: A factorial design study. Chemical and Pharmaceutical Bulletin, 59(5), 579–586.
18. Nagpal, M., & Sood, S. (2013). Role of curcumin in systemic and ocular diseases: An overview. Indian Journal of Clinical Biochemistry, 28(3), 282–290.
19. Vats, M., Mishra, N., & Verma, A. (2016). Formulation and evaluation of thermosensitive in situ gel of moxifloxacin hydrochloride for ophthalmic drug delivery. International Journal of Drug Delivery, 8(2), 133–144.
20. Yadav, S., Mishra, M., & Tiwari, A. (2022). Recent advances in curcumin nanoformulations for ocular application. Artificial Cells, Nanomedicine, and Biotechnology, 50(1), 142–153.